Our Organoid Lab is actively engaged in developing PDOs from a broad spectrum of human cancers. Established pipeline analytics support drug selection based on genetically-annotated PDOs and small-molecules chemical screens. Our lab brings together cancer scientists, specialist technical staff and partnership with clinicians to advance PDO applications in new and existing drug discoveries. We welcome R&D collaborations and commercial partnerships.
Areas of focus:
Personalized Medicine: Select suitable drug options for individual patient through genome-guided PDO drug testing to assist clinical decision. A report on drug sensitivity profile will be provided to users of this service.
Drug Discovery: Provide a PDO platform for preclinical drugs testing and pipeline compounds screening. PDO models from normal liver are also available to assess new drugs / compounds for hepatoxicity. A full report on every compound screened will be provided.
Living Biobank of healthy and tumor PDOs that represent a unique repertoire from East Asian ethnicity. PDO lines established from liver cancer, colon cancer, rectal cancer, lung adenocarcinoma, pancreatic ductal adenocarcinoma and triple negative breast cancer are accessible for academic research and commercial licensing. The Office of Research and Knowledge Transfer Services (ORKTS) under The Chinese University of Hong Kong (CUHK) will be liaised for MTA, contractual research and commercial interests.
For services request, research collaboration and commercial purposes, please contact us at email@example.com.